|
1
|
Diamond E, Riches J, Faltas B, Tagawa ST
and Nanus DM: Immunologics and chemotherapeutics for renal cell
carcinoma. Semin Intervent Radiol. 31:91–97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rydzanicz M, Wrzesiński T, Bluyssen HA and
Wesoly J: Genomics and epigenomics of clear cell renal cell
carcinoma: recent developments and potential applications. Cancer
Lett. 341:111–126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chowdhury S, Matrana MR, Tsang C, Atkinson
B, Choueiri TK and Tannir NM: systemic therapy for metastatic
non-clear-cell renal cell carcinoma: recent progress and future
directions. Hematol Oncol Clin North Am. 25:853–869. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garg D and Cohen SM: miRNAs and aging: A
genetic perspective. Ageing Res Rev. 2014:3–8. 2014. View Article : Google Scholar
|
|
5
|
Choi JD and Lee JS: Interplay between
epigenetics and genetics in cancer. Genomics Inf. 11:164–173. 2013.
View Article : Google Scholar
|
|
6
|
Watanabe K and Takai D: Disruption of the
expression and function of microRNAs in lung cancer as a result of
epigenetic changes. Front Genet. 4:2752013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao JJ, Yang J, Lin J, et al:
Identification of miRNAs associated with tumorigenesis of
retinoblastoma by miRNA microarray analysis. Childs Nerv Syst.
25:13–20. 2009. View Article : Google Scholar
|
|
8
|
von Frowein J, Pagel P, Kappler R, von
Schweinitz D, Roscher A and Schmid I: MicroRNA-492 is processed
from the keratin 19 gene and up-regulated in metastatic
hepatoblastoma. Hepatology. 53:833–842. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yoon KA, Yoon H, Park S, et al: The
prognostic impact of microRNA sequence polymorphisms on the
recurrence of patients with completely resected non-small cell lung
cancer. J Thorac Cardiovasc Surg. 144:794–807. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gaedcke J, Grade M, Camps J, et al: The
rectal cancer microRNAome - microRNA expression in rectal cancer
and matched normal mucosa. Clin Cancer Res. 18:4919–4930. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schultz NA, Werner J, Willenbrock H, et
al: MicroRNA expression profiles associated with pancreatic
adenocarcinoma and ampullary adenocarcinoma. Mod Pathol.
25:1609–1622. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hui AB, Lin A, Xu W, et al: Potentially
prognostic miRNAs in HPV-associated oropharyngeal carcinoma. Clin
Cancer Res. 19:2154–2162. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kupcinskas J, Wex T, Link A, et al: Gene
polymorphisms of micrornas in Helicobacter pylori-induced high risk
atrophic gastritis and gastric cancer. PLoS One. 9:e874672014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu X, Weng L, Li X, et al: Identification
of a 4-microRNA signature for clear cell renal cell carcinoma
metastasis and prognosis. PLoS One. 7:e356612012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kim JG, Kim TO, Bae JH, et al:
Epigenetically regulated MIR941 and MIR1247 target gastric cancer
cell growth and migration. Epigenetics. 9:1018–1030. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Suzuki H, Maruyama R, Yamamoto E and Kai
M: Epigenetic alteration and microRNA dysregulation in cancer.
Front Genet. 4:2582013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu Y, Liu J, Jiang B, et al: Mir-199a-5p
loss up-regulated DDR1 aggravated colorectal cancer by activating
epithelial-to-mesenchymal transition related signaling. Dig Dis
Sci. 59:2163–2172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shapiro JA: Epigenetic control of mobile
DNA as an interface between experience and genome change. Front
Genet. 5:872014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang Z, Chen Y, Tang J and Xie X:
Frequent loss expression of and promotor hypermethylation in human
cancers: a meta-analysis and systematic review. Pak J Med Sci.
30:432–437. 2014.PubMed/NCBI
|
|
20
|
Izutsu N, Maesawa C, Shibazaki M, et al:
Epigenetic modification is involved in aberrant expression of class
III β-tubulin, TUBB3, in ovarian cancer cells. Int J Oncol.
32:1227–1235. 2008.PubMed/NCBI
|
|
21
|
Song K, Han C, Zhang J, et al: Epigenetic
regulation of MicroRNA-122 by peroxisome proliferator activated
receptor-gamma and hepatitis b virus X protein in hepatocellular
carcinoma cells. Hepatology. 58:1681–1692. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fetahu IS, Höbaus J, Aggarwal A, et al:
Calcium-sensing receptor silencing in colorectal cancer is
associated with promoter hyper-methylation and loss of acetylation
on histone 3. Int J Cancer. 135:2014–2023. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu Z, Li H and Jin P: Epigenetics-based
therapeutics for neuro-degenerative disorders. Curr Transl Geriatr
Exp Gerontol Rep. 1:229–236. 2012. View Article : Google Scholar
|
|
24
|
Wang Y and Tjandra N: Structural insights
of tBid, the caspase-8-activated Bid, and its BH3 domain. J Biol
Chem. 288:35840–35851. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Renault TT and Chipuk JE: Getting away
with murder: how does the BCL-2 family of proteins kill with
immunity? Ann NY Acad Sci. 1285:59–79. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maurya SK, Tewari M, Sharma B and Shukla
HS: Expression of procaspase 3 and activated caspase 3 and its
relevance in hormone-responsive gallbladder carcinoma chemotherapy.
Korean J Intern Med. 28:573–578. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Connolly PF, Jäger R and Fearnhead HO: New
roles for old enzymes: killer caspases as the engine of cell
behavior changes. Front Physiol. 5:1492014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nilsson GM, Akhtar N, Kannius-Janson M and
Baeckström D: Loss of E-cadherin expression is not a prerequisite
for c-erbB2-induced epithelial-mesenchymal transition. Int J Oncol.
45:82–94. 2014.PubMed/NCBI
|
|
29
|
Ponce E, Louie MC and Sevigny MB: Acute
and chronic cadmium exposure promotes E-cadherin degradation in
MCF7 breast cancer cells. Mol Carcinog. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sutoh Yoneyama M, Hatakeyama S, Habuchi T,
et al: Vimentin intermediate filament and plectin provide a
scaffold for inva-dopodia, facilitating cancer cell invasion and
extravasation for metastasis. Eur J Cell Biol. 93:157–169. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fu CH, Lin RJ, Yu J, et al: A novel
oncogenic role of inositol phosphatase SHIP2 in ER-negative breast
cancer stem cells: involvement of JNK/Vimentin activation. Stem
Cells. 32:2048–2060. 2014. View Article : Google Scholar : PubMed/NCBI
|
